Repository logo
 
Loading...
Project Logo
Research Project

Untitled

Authors

Publications

Enantioselective quantification of fluoxetine and norfluoxetine by HPLC in wastewater effluents
Publication . Ribeiro, Ana R.; Maia, Alexandra S.; Moreira, Irina S.; Afonso, Carlos M.; Castro, Paula M.L.; Tiritan, Maria E.
Microbial degradation is the most important process to remove organic pollutants in Waste Water Treatment Plants. Regarding chiral compounds this process is normally enantioselective and needs the suitable analytical methodology to follow the removal of both enantiomers in an accurate way. Thus, this paper describes the development and validation of an enantioselective High Performance Liquid Chromatography with Fluorescence Detection (HPLC-FD) method for simultaneous analysis of fluoxetine (FLX) and norfluoxetine (NFLX) in wastewater effluents. Briefly, this method preconcentrated a small volume of wastewater samples (50 mL) on 500 mg Oasis MCX cartridges and used HPLC-FD with a vancomycin-based chiral stationary phase under reversed mode for analyses. The optimized mobile phase was EtOH/aqueous ammonium acetate buffer (92.5/7.5, v/v) at pH 6.8. The effect of EtOH percentage, buffer concentration, pH, column oven temperature and flow rate on chromatographic parameters was systematically investigated. The developed method was validated within the wastewater effluent used in microcosms laboratory assays. Linearity (R2 > 0.99), selectivity and sensitivity were achieved in the range of 4.0–60 ng mL 1 for enantiomers of FLX and 2.0–30 ng mL 1 for enantiomers of NFLX. The limits of detection were between 0.8 and 2.0 ng mL 1 and the limits of quantification were between 2.0 and 4.0 ng mL 1 for both enantiomers of FLX and the enantiomers of its demethylated metabolite NFLX. The validated method was successfully applied and proved to be robust to follow the degradation of both enantiomers of FLX in wastewater samples, during 46 days.
Photodegradation of pharmaceutical persistent pollutants using hydroxyapatite-based materials
Publication . Brazon, E. Marquez; Piccirillo, C.; Moreira, I. S.; Castro, P. M. L.
Pharmaceutical persistent pollutants pose a serious threat to the environment. The aim of this study was to use, for the first time, hydroxyapatite-based biomaterials as photocatalysts to degrade micropollutants. Diclofenac and fluoxetine were selected for these initial tests. Hydroxyapatite (Ca10(PO4)(OH)2, HAp) is one of the most commonly used biomaterials/bioceramics, being a major constituent of bone. In this work sustainable HAp-based materials of marine origin, obtained from cod fish bones, were used; these photocatalysts were previously fully studied and characterised. Both singlephase HAp and HApetitania multicomponent materials (1 wt% TiO2) were employed as UV light photocatalysts, the latter showing better performance, indicated by higher degradation rates of both compounds. The HAp-titania photocatalyst showed excellent degradation of both persistent pollutants, the maximum degradation performance being 100% for fluoxetine and 92% for diclofenac, with pollutant and photocatalyst concentrations of 2 ppm and 4 g/L, respectively. Variations in features such as pollutant and photocatalyst concentrations were investigated, and results showed that generally fluoxetine was degraded more easily than diclofenac. The photocatalyst's crystallinity was not affected by the photodegradation reaction; indeed the material exhibited good photostability, as the degradation rate did not decrease when the material was reused. Tests were also performed using actual treated wastewater; the photocatalyst was still effective, even if with lower efficiency (-20% and -4% for diclofenac and fluoxetine, respectively). TOC analysis showed high but incomplete mineralisation of the pollutants (maximum 60% and 80% for DCF and FXT, respectively).
Enrichment of bacterial strains for the biodegradation of diclofenac and carbamazepine from activated sludge
Publication . Bessa, V. S.; Moreira, I. S.; Tiritan, M. E.; Castro, P. M. L.
Carbamazepine and diclofenac have been pointed out as important markers for environmental pollution by pharmaceuticals. This study reports on the isolation of bacterial strains capable to degrade these micropollutants from activated sludge of a municipal wastewater treatment plant (WWTP). After selective enrichments, one strain able to degrade diclofenac and two strains able to degrade carbamazepine were isolated. The strains were identified by 16S rRNA gene sequencing. Strain Brevibacterium sp. D4 was able to biodegrade 35% of 10 mg L−1 of diclofenac as a sole carbon source; periodic feeding with acetate as a supplementary carbon source resulted in enhancing biodegradation to levels up to 90%, with a concomitant increase of the biodegradation rate. Strains Starkeya sp. C11 and Rhizobium sp. C12 were able to biodegrade 30% of 10 mg L−1 of carbamazepine as a sole carbon source; supplementation with acetate did not improve the biodegradation of carbamazepine by these strains. The activated sludge harboured bacteria capable to degrade the two top priority environmental contaminants and may be potentially useful for biotechnological applications.
Aerobic granular sludge: treatment of wastewaters containing toxic compounds
Publication . Amorim, Catarina L.; Moreira, Irina S.; Duque, Anouk F.; Loosdrecht, Mark C. M. van; Castro, P. M. L.
Aerobic Granular Sludge (AGS) has been successfully applied for carbon, nitrogen and phosphorous removal from wastewaters, in a single tank, reducing the space and energy requirements. This is especially beneficial for, often space restricted, industrial facilities. Moreover, AGS holds a promise for the toxic pollutants removal, due to its layered and compact structure and the bacteria embedding in a protective extracellular polymeric matrix. These outstanding features contribute to AGS tolerance to toxicity and stability. Strategies available to deal with toxic compounds, namely granulation with effluents containing toxics and bioaugmentation, are addressed here. Different applications for the toxics/micropollutants removal through biosorption and/or biodegradation are presented, illustrating the technology versatility. The anthropogenic substances effects on system performance and bacterial populations established within AGS are also addressed. Combination of contaminants removal to allow water discharge, and simultaneous valuable products recovery are presented as final remark.
Photocatalytic degradation of diclofenac by hydroxyapatite-TiO2 composite material: Identification of transformation products and assessment of toxicity
Publication . Murgolo, Sapia; Moreira, Irina S.; Piccirillo, Clara; Castro, Paula M. L.; Ventrella, Gianrocco; Cocozza, Claudio; Mascolo, Giuseppe
Diclofenac (DCF) is one of the most detected pharmaceuticals in environmental water matrices and is known to be recalcitrant to conventional wastewater treatment plants. In this study, degradation of DCF was performed in water by photolysis and photocatalysis using a new synthetized photocatalyst based on hydroxyapatite and TiO2 (HApTi). A degradation of 95% of the target compound was achieved in 24 h by a photocatalytic treatment employing the HApTi catalyst in comparison to only 60% removal by the photolytic process. The investigation of photo-transformation products was performed by means of UPLC-QTOF/MS/MS, and for 14 detected compounds in samples collected during treatment with HApTi, the chemical structure was proposed. The determination of transformation product (TP) toxicity was performed by using different assays: Daphnia magna acute toxicity test, Toxi-ChromoTest, and Lactuca sativa and Solanum lycopersicum germination inhibition test. Overall, the toxicity of the samples obtained from the photocatalytic experiment with HApTi decreased at the end of the treatment, showing the potential applicability of the catalyst for the removal of diclofenac and the detoxification of water matrices.

Organizational Units

Description

Keywords

Contributors

Funders

Funding agency

Fundação para a Ciência e a Tecnologia

Funding programme

SFRH

Funding Award Number

SFRH/BPD/87251/2012

ID